前列腺癌大分割放疗(HYDRA):MARCAP联盟随机试验的个体患者数据荟萃分析
等剂量MHFRT与剂量递增MHFRT的无进展生存期均与CFRT无显著差异,但剂量递增MHFRT与更高的医生评分和患者报告的肠道毒性相关。作者认为等剂量方案(如60 Gy分20次)应作为局限性前列腺癌的标准MHFRT方案。
要点
- 等剂量MHFRT与剂量递增MHFRT相比CFRT均未显著改善无进展生存期。
- 剂量递增MHFRT的≥2级胃肠道毒性几率和肠道生活质量下降几率显著高于CFRT。
- 作者认为等剂量方案(如60 Gy分20次)应作为局限性前列腺癌的标准MHFRT方案。
核心结论
- 等剂量MHFRT和剂量递增MHFRT与CFRT相比疗效相似,但剂量递增MHFRT与更高的医生评分和患者报告的肠道毒性相关。
- 作者认为等剂量方案(如60 Gy分20次)应作为局限性前列腺癌的标准MHFRT方案。
研究设计与样本
- 研究类型为个体患者数据荟萃分析,识别比较CFRT与MHFRT的3期随机试验。
- 纳入标准包括已发表疗效和晚期毒性个体患者数据、CFRT组使用现代剂量放疗(≥70 Gy按2 Gy等效剂量)。
- 共纳入7项3期试验,其中3项比较CFRT与等剂量MHFRT(3454例患者),4项比较CFRT与剂量递增MHFRT(2426例患者)。
- 系统文献检索于2023年12月15日初步进行,并于2025年1月8日重新进行。
- 三项独立荟萃分析分别比较疗效(主要终点为无进展生存期)、医生评分的晚期毒性(共同主要终点为晚期≥2级泌尿生殖毒性和晚期≥2级胃肠道毒性)和患者报告结局(共同主要终点为患者报告泌尿或肠道生活质量有临床意义的下降)。
主要发现
- 等剂量MHFRT的中位随访为5.4年(IQR 4.6-7.2),剂量递增MHFRT的中位随访为7.1年(IQR 5.7-8.4)。
- 无进展生存期无差异:等剂量MHFRT vs CFRT的HR为0.92(95% CI 0.81-1.05;p=0.21),剂量递增MHFRT vs CFRT的HR为0.94(95% CI 0.82-1.09;p=0.43)。
- ≥2级泌尿生殖毒性几率未增加:等剂量MHFRT的OR为1.16(95% CI 0.86-1.57;p=0.32),剂量递增MHFRT的OR为1.20(95% CI 0.95-1.51;p=0.13)。
- ≥2级胃肠道毒性几率:剂量递增MHFRT显著更高(OR 1.48,95% CI 1.14-1.92;p=0.0035),等剂量MHFRT无显著差异(OR 1.30,95% CI 0.59-2.87;p=0.51)。
- 患者报告结局:等剂量MHFRT的泌尿生活质量下降OR为1.03(95% CI 0.51-2.09;p=0.93),肠道生活质量下降OR为0.76(95% CI 0.40-1.43;p=0.39);剂量递增MHFRT的肠道生活质量下降OR为1.68(95% CI 1.07-2.61;p=0.023),泌尿生活质量下降OR为1.57(95% CI 0.87-2.85;p=0.13)。
关键数值与推荐
- 等剂量MHFRT与CFRT相比无进展生存期HR 0.92(95% CI 0.81-1.05;p=0.21)。
- 剂量递增MHFRT与CFRT相比无进展生存期HR 0.94(95% CI 0.82-1.09;p=0.43)。
- 剂量递增MHFRT与CFRT相比≥2级胃肠道毒性OR 1.48(95% CI 1.14-1.92;p=0.0035)。
- 剂量递增MHFRT与CFRT相比肠道生活质量下降OR 1.68(95% CI 1.07-2.61;p=0.023)。
- 作者推荐等剂量方案(如60 Gy分20次)应作为局限性前列腺癌的标准MHFRT方案。
临床怎么用
- 作者认为等剂量MHFRT方案(如60 Gy分20次)应作为局限性前列腺癌的标准MHFRT方案。
- 剂量递增MHFRT与更高的医生评分和患者报告的肠道毒性相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trials comparing moderately hypofractionated radiotherapy (MHFRT) to conventionally-fractionated radiotherapy (CFRT) for prostate cancer have varied considerably in intent (non-inferiority vs superiority) and MHFRT dose. We compare the efficacy and toxicity profiles of isodose MHFRT and dose-escalated MHFRT. METHODS: This was an individual patient data meta-analysis that identified randomised phase 3 trials of CFRT versus MHFRT that had published individual patient-level data on efficacy and late toxicity. A systematic literature search using MEDLINE, Embase, trial registries, the Web of Science, Scopus, and relevant conference proceedings was initially conducted on Dec 15, 2023, and was re-conducted on Jan 8, 2025. Trials that did not publish efficacy data, did not publish late toxicity data, or did not use modern dose radiotherapy (≥70 Gy in 2 Gy equivalents) in the CFRT group were excluded. Individual patient data were provided to MARCAP by study investigators. Three separate meta-analyses were designed to compare efficacy (primary endpoint was progression-free survival), physician-scored late toxicity (co-primary endpoints were late grade 2 or higher genitourinary and late grade 2 or higher gastrointestinal toxic effects), and patient-reported outcomes (co-primary endpoints were clinically-significant decrements in patient-reported urinary or bowel quality of life) between patients receiving CFRT versus MHFRT. FINDINGS: We identified 1696 records for review. Seven phase 3 trials comparing MHFRT with CFRT were eligible for inclusion in our analysis. Individual patient data were obtained from these seven studies (3454 patients from three trials comparing CFRT with isodose MHFRT and 2426 patients from four trials comparing CFRT with dose-escalated MHFRT). At a median follow-up of 5·4 years (IQR 4·6-7·2) for isodose MHFRT and 7·1 years (5·7-8·4) for dose-escalated MHFRT, no differences in progression-free survival were detected (hazard ratio 0·92, 95% CI 0·81-1·05; p=0·21 and 0·94, 0·82-1·09; p=0·43 respectively). No increased odds of grade 2 or higher genitourinary toxic effects were identified for either isodose (odds ratio [OR] 1·16, 95 CI% 0·86-1·57; p=0·32) or dose-escalated MHFRT (1·20, 0·95-1·51; p=0·13). The odds of grade 2 or higher gastrointestinal toxic effects were significantly higher with dose-escalated (OR 1·48, 95% CI 1·14-1·92; p=0·0035) but not isodose MHFRT (1·30, 0·59-2·87; p=0·51). Isodose MHFRT was not found to show different odds of urinary quality-of-life decrement (OR 1·03, 95% CI 0·51-2·09; p=0·93) or bowel quality-of-life decrement (0·76, 0·40-1·43; p=0·39). Dose-escalated MHFRT was associated with greater odds of bowel quality-of-life decrement (OR 1·68, 95% CI 1·07-2·61; p=0·023), but no evidence of greater urinary quality-of-life decrement was found (1·57, 0·87-2·85; p=0·13). INTERPRETATION: Isodose MHFRT and dose-escalated MHFRT both have similar efficacy compared with CFRT, but dose-escalated MHFRT is associated with higher physician-scored and patient-reported bowel toxicity. Isodose regimens, eg, 60 Gy in 20 fractions, should be the standard MHFRT regimen for localised prostate cancer. FUNDING: None.
引用
- Kishan AU, Sun Y, Tree AC, et al. Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium. Lancet Oncol. 2025. PMID: 40112848. doi:10.1016/S1470-2045(25)00034-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。